Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: Aberrant expression of inflammatory molecules, such as inducible nitric oxide (NO) synthase (iNOS), has been linked to cancer, suggesting that their inhibition is a rational therapeutic approach. Whereas iNOS expression in melanoma and other cancers is associated with poor clinical prognosis, in vitro and in vivo studies suggest that iNOS and NO can have both protumor and antitumor effects. We tested the hypothesis that targeted iNOS inhibition would interfere with human melanoma growth and survival in vivo in a preclinical model. Experimental Design: We used an immunodeficient non-obese diabetic/severe combined immunodeficient xenograft model to test the susceptibility of two different human melanoma lines to the orally-given iNOS-selective small molecule antagonist N6-(1-iminoethyl)-l-lysine-dihydrochloride (L-nil) with and without cytotoxic cisplatin chemotherapy. Results: L-nil significantly inhibited melanoma growth and extended the survival of tumor-bearing mice. L-nil treatment decreased the density of CD31+ microvessels and increased the number of apoptotic cells in tumor xenografts. Proteomic analysis of melanoma xenografts with reverse-phase protein array identified alterations in the expression of multiple cell signaling and survival genes after L-nil treatment. The canonical antiapoptotic protein Bcl-2 was downregulated in vivo and in vitro after L-nil treatment, which was associated with increased susceptibility to cisplatin-mediated tumor death. Consistent with this observation, combination therapy with L-nil plus cisplatin in vivo was more effective than either drug alone, without increased toxicity. Conclusions: These data support the hypothesis that iNOS and iNOS-derived NO support tumor growth in vivo and provide convincing preclinical validation of targeted iNOS inhibition as therapy for solid tumors. Clin Cancer Res; 16(6); 1834–44
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · cited 1×
“No chemical inhibitor is completely selective, and in fact many so-called “targeted” agents can act on a relatively broad set of molecular targets (43).”
BackgroundMethods to detect nitric oxide and its metabolites in biological samples
Bryan, N. S., & Grisham, M. B. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.04.026 · Cited by 1,005
Hansel, T. T., Kharitonov, S. A., Donnelly, L. E., Erin, E. M., Currie, M. G., Moore, W. M., Manning, P. T., Recker, D. P., & Barnes, P. J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0633fje · Cited by 208
S-Nitrosylation of Bcl-2 Inhibits Its Ubiquitin-Proteasomal Degradation
Azad, N., Vallyathan, V., Wang, L., Tantishaiyakul, V., Stehlik, C., Leonard, S. S., & Rojanasakul, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602551200 · Cited by 194 · cited 3×
“Bcl-2 is not only a critical regulator of cell death in response to a variety of stimuli, but its posttranslational stability is also known to be regulated by NO via nitrosylation of key cysteine residues (14).”
BackgroundThomas, D. D., Miranda, K. M., Colton, C. A., Citrin, D., Espey, M. G., & Wink, D. A. (2003) · Antioxidants & Redox Signaling · doi:10.1089/152308603322110887 · Cited by 89 · cited 1×
“At lower levels, NO can affect signal transduction pathways by interacting with metal ligands of proteins (8) or covalently modifying proteins through nitration and nitrosylation (9, 10).”
Background
Cited by
Inducible nitric oxide synthase: Regulation, structure, and inhibition
Cinelli, M. A., Do, H. T., Miley, G. P., & Silverman, R. B. (2020) · Medicinal Research Reviews · doi:10.1002/med.21599 · Cited by 889
Gasotransmitters in cancer: from pathophysiology to experimental therapy
Szabo, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.1 · Cited by 717
Hossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
Arginase: A Multifaceted Enzyme Important in Health and Disease
Caldwell, R. W., Rodriguez, P. C., Toque, H. A., Narayanan, S. P., & Caldwell, R. B. (2018) · Physiological Reviews · doi:10.1152/physrev.00037.2016 · Cited by 495
The yin and yang of nitric oxide in cancer progression
Burke, A. J., Sullivan, F. J., Giles, F. J., & Glynn, S. A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt034 · Cited by 370
Metadata
- Authors
- Sikora, A. G., Gelbard, A., Davies, M. A., Sano, D., Ekmekcioglu, S., Kwon, J., Hailemichael, Y., Jayaraman, P., Myers, J. N., Grimm, E. A., & Overwijk, W. W.
- Venue
- Clinical Cancer Research
- Published
- 2010-03-14
- Volume
- 16
- Issue
- 6
- Pages
- 1834-1844
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2159435304
- Cited by
- 121
- References
- 6
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-3123
- The paper
- Sikora, A. G., Gelbard, A., Davies, M. A., Sano, D., Ekmekcioglu, S., Kwon, J., Hailemichael, Y., Jayaraman, P., Myers, J. N., Grimm, E. A., & Overwijk, W. W. (2010). Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-3123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.